Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.63 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | FABP2 | P12104 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.63 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.63 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348404 | 1.00 | AKR1C3 (0.63) | AKR1C3AKR1C2LMNAPTGS1MEN1 | |
| SCHEMBL2918748 | 1.00 | AKR1C3 (0.63) | AKR1C3AKR1C2LMNAPTGS1MEN1 | |
| SCHEMBL10829871 | 0.84 | AKR1C3 (0.59) | AKR1C3AKR1C2LMNAPTGS1MEN1 | |
| SCHEMBL6690493 | 0.82 | APP (0.65) | AKR1C3AKR1C2LMNAPTGS1MEN1 | |
| SCHEMBL2739316 | 0.81 | AKR1C3 (0.68) | AKR1C3AKR1C2LMNAPTGS1MEN1 | |
| SCHEMBL9420889 | 0.81 | CSNK2A1 (0.42) | AKR1C3AKR1C2LMNAPTGS1MEN1 | |
| SCHEMBL27741049 | 0.80 | AKR1C3 (0.55) | AKR1C3AKR1C2LMNAPTGS1MEN1 | |
| SCHEMBL7167173 | 0.80 | GRIA4 (0.51) | AKR1C3AKR1C2LMNAPTGS1MEN1 | |
| SCHEMBL4948848 | 0.79 | AKR1C3 (0.47) | AKR1C3AKR1C2LMNAPTGS1MEN1 | |
| SCHEMBL9446938 | 0.79 | AKR1C3 (0.60) | AKR1C3AKR1C2LMNAPTGS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5998660-A | BY-PRODUCT INHIBITION | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1999-12-07 | — | — | US | claimed |
| US-5739352-A | Process for preparing carboxylic acids | UNITED CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-04-14 | — | — | US | claimed |
| JP-55127336-A | — | — | None | — | — | JP | disclosed |
| CN-120463591-A | Preparation method of low-cost high-purity flurbiprofen | 云南省药物研究所 | 2025-08-12 | — | — | CN | disclosed |
| US-20230293557-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | MEDICON PHARMACEUTICALS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11684652-B2 | HMGB1 antagonist treatment of acute lung injury | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684652-B2 | HMGB1 antagonist treatment of acute lung injury | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230149505-A1 | HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSIS | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149505-A1 | HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSIS | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-05-18 | — | — | US | disclosed |
| US-11524048-B2 | HMGB1 antagonist treatment of severe sepsis | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-12-13 | — | — | US | disclosed |
| CN-107847484-B | Nitroxide free radicals for the treatment of respiratory diseases | 耶路撒冷希伯来大学伊森姆研究发展公司 | 2021-07-06 | — | — | CN | disclosed |
| WO-2010009215-A1 | NICOTINIC ACID RECEPTOR AGONIST COMPOUNDS USEFUL TO TREAT METABOLIC SYNDROMES | SCHERING CORPORATION (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010009212-A1 | NIACIN DERIVATIVES USEFUL TO TREAT METABOLIC SYNDROMES | SCHERING CORPORATION (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2008115385-A2 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008074717-A2 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYLPROPANOLS HAVING A PROFEN-LIKE SUBSTITUTED ARYL RESIDUE | ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA (IT) | 2008-06-26 | — | — | WO | disclosed |
| CN-1138764-C | Isoxazole derivatives | ס����ҩ��ʽ���� | 2004-02-18 | — | — | CN | disclosed |
| CN-1252794-A | Isoxazole derivatives | SUMITOMO PHARMA (JP) | 2000-05-10 | — | — | CN | disclosed |
| US-5998660-A | BY-PRODUCT INHIBITION | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| US-5739352-A | Process for preparing carboxylic acids | UNITED CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-04-14 | — | — | US | disclosed |
| JP-S55127336-A | PREPARATION OF ALPHA-(2-FLUORO-4-(1,1'-BIPHENYLYL))-PROPANAL | DAITO KOEKI KK | 1980-10-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149505-A1 | HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSIS | HMGB1, HMGB3, HMGB2 | AKR1C3 2471/4885AKR1C2 3808/4885LMNA 607/4885 |
| US-11524048-B2 | HMGB1 antagonist treatment of severe sepsis | HMGB1, HMGB3, HMGB2 | AKR1C3 2471/4885AKR1C2 3808/4885LMNA 607/4885 |
| US-11684652-B2 | HMGB1 antagonist treatment of acute lung injury | HMGB1, HMGB3, HMGB2 | AKR1C3 2128/4885AKR1C2 3346/4885LMNA 235/4885 |
| US-20230293557-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | PDE6C, PDE6H, PDE6D | AKR1C3 191/4885AKR1C2 245/4885LMNA 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.